Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avian Encephalomyelitis Vaccine (MEVAC) is a veterinary vaccine developed by Middle East for Vaccines (MEVAC) for the immunization of poultry against Avian Encephalomyelitis (AE). AE is an infectious viral disease caused by the Avian Encephalomyelitis Virus (AEV), a member of the Picornaviridae family, which primarily affects young chickens, causing neurological symptoms such as ataxia and tremors (often called "epidemic tremors"). In adult laying birds, the virus causes a temporary but significant drop in egg production. The vaccine is typically a live-attenuated formulation designed to induce a protective immune response in pullets before they begin laying. This immunization protects the hens from production drops and ensures the transfer of maternal antibodies to their progeny, providing passive immunity to chicks during their first few weeks of life when they are most susceptible to the disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Avian Encephalomyelitis Vaccine (MEVAC).